Amgen Inc.AMGN
Close of Friday, October 23, 2026 · Amgen Inc. is trading above its Pivot, OnlyAlpha's long-term trend line.
Price
$439.22
vs its Pivot
+18.2%
OnlyAlpha Score
69
Trend
Above its Pivot
Last 12 months. Solid line: price. Dashed green: the Pivot.
Returns
| 1 month | Year to date | 1 year | 3 years / yr | 5 years / yr |
|---|---|---|---|---|
| +8.2% | +36.9% | +52.5% | +19.2% | +19.8% |
Dividend: $9.94 a share over the last 12 months, a 2.26% yield at today's price.
Who runs and owns it
In these funds
IBB · 7.68%IYH · 3.52%HDV · 2.73%DGRO · 1.18%IQQ · 0.92%OEF · 0.45%
Big investors that own it (latest 13F)
| CalPERS | 0.3% of holdings |
| New York State Common | 0.3% of holdings |
Suppliers, customers and partners
Sells to AMGN
| Arrowhead Pharmaceuticals | olpasiran royalties (assigned to Royalty Pharma) |
AMGN sells to
| McKesson | >10% of revenue each; 77% of gross rev combined |
| Cencora | >10% of revenue each; 77% of gross rev combined |
| Cardinal Health | >10% of revenue each; 77% of gross rev combined |
Partners and deals
| BeOne Medicines (formerly BeiGene) | Asia-Pacific commercial partner |
| Astellas Pharma | Asia-Pacific commercial partner |
From the companies' own annual reports filed with the SEC.
Healthcare · Pharma
Get AMGN in your free daily emailAfter every close: whether AMGN is above or below its Pivot, its OnlyAlpha Score, and any new buy or sell signal, along with the rest of your list.
Track AMGN free → Full Stock check
Track AMGN free → Full Stock check